1
|
Olney KB, Olney WJ, McTigue SM, Howard JI, Stadler LP. Things We Do for No Reason™: Prescribe cefdinir for treatment of common infections. J Hosp Med 2024. [PMID: 38824604 DOI: 10.1002/jhm.13415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 05/07/2024] [Accepted: 05/11/2024] [Indexed: 06/03/2024]
Affiliation(s)
- Katie B Olney
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA
- Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA
| | - William J Olney
- Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA
- Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA
| | - Sean M McTigue
- Department of Pediatrics: Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, Kentucky, USA
- Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| | - Joel I Howard
- Department of Pediatrics: Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, Kentucky, USA
- Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| | - Laura P Stadler
- Department of Pediatrics: Division of Infectious Diseases, University of Kentucky HealthCare, Lexington, Kentucky, USA
- Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| |
Collapse
|
2
|
de Macedo V, Meneghete BP, Koaski JC, Albuquerque AS, Fachi MM. Doxycycline for Multidrug-Resistant Gram-Negative Bacterial Infection Treatment: A Scoping Review. J Glob Infect Dis 2023; 15:95-100. [PMID: 37800083 PMCID: PMC10549905 DOI: 10.4103/jgid.jgid_34_23] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 03/22/2023] [Accepted: 05/19/2023] [Indexed: 10/07/2023] Open
Abstract
Introduction Multidrug-resistant bacterial infections limit available therapeutic options. Doxycycline is an old antibiotic from the tetracycline class that exhibits a wide antibacterial action, including Gram-negative bacteria (GNB), and could be an alternative for the treatment of multidrug-resistant (MDR) Enterobacteriaceae. The study aimed to systematically identify, evaluate, and summarize the results of studies related to outcomes of treatments for MDR-GNB infections in patients treated with doxycycline. Methods This review was conducted in four databases during weeks 41-52 of 2022: PubMed, Medline, Scopus, and Web of Science, from the earliest year available on each database to December 2022. Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines were followed in conducting this study, and PICO was used for the research question of this review. Results This scoping review found 8 retrospective studies that included 59 patients. Of these, 69% were treated for ventilator-associated pneumonia (VAP), 27% for urinary tract infections, 2% for bloodstream infections, and 2% for wound infections, both of which were associated with VAP. The usual dosage of doxycycline was 100 mg intravenously or orally. Clinical and microbiologic improvements were achieved in 81.3% and 87% of all patients, respectively. The mortality rate was 17.3% and was exclusively due to VAP. Conclusions Doxycycline showed promising results in this review; however, randomized clinical trials or prospective cohorts are recommended to demonstrate the efficacy of doxycycline in the treatment of MDR infections with GNB.
Collapse
Affiliation(s)
- Viviane de Macedo
- Department of Infectious Diseases, Hospital Infection Control and Epidemiology Center, Santa Casa de Curitiba, Curitiba, Paraná, Brazil
| | - Bruno Pandolfo Meneghete
- Department of Infectious Diseases, Medicine School, Positive University, Curitiba, Paraná, Brazil
| | - José Cassiano Koaski
- Department of Infectious Diseases, Medicine School, Positive University, Curitiba, Paraná, Brazil
| | - Ariádne Sousa Albuquerque
- Department of Infectious Diseases, Hospital Infection Control and Epidemiology Center, Santa Casa de Curitiba, Curitiba, Paraná, Brazil
| | | |
Collapse
|
3
|
Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis 2023; 76:683-691. [PMID: 35903011 DOI: 10.1093/cid/ciac615] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 06/28/2022] [Accepted: 07/22/2022] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Doxycycline has been recommended as a treatment option for non-severe community-acquired pneumonia (CAP) in adults. We sought to review the evidence for the efficacy of doxycycline in adult patients with mild-to-moderate CAP. METHODS We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) of doxycycline versus comparator to assess the clinical efficacy. The primary outcome was the clinical cure rate. Random effects model meta-analyses were used to generate pooled odds ratio (OR) and evaluate heterogeneity (I2). Risk of bias (RoB) and quality of evidence (QoE) were evaluated using the Cochrane Risk of Bias 2.0 tool and GRADE methods, respectively. RESULTS We included 6 RCTs with 834 clinically evaluable patients. The trials were performed between 1984 and 2004. Comparators were 3 macrolides (roxithromycin, spiramycin, and erythromycin) and 3 fluoroquinolones (ofloxacin, fleroxacin, and levofloxacin). Four trials had an overall high RoB. The clinical cure rate was similar between the doxycycline and comparator groups (87.2% [381/437] vs 82.6% [328/397]; OR 1.29 [95% confidence interval {CI}: .73-2.28]; I2 = 30%; low QoE). Subgroup analysis of two studies with a low RoB showed significantly higher clinical cure rates in the doxycyline group (87.1% [196/225] vs 77.8% [165/212]; OR 1.92 [95% CI: 1.15-3.21]; P = .01; I2 = 0%). Adverse event rates were comparable between the doxycycline and comparator groups. CONCLUSIONS The efficacy of doxycycline was comparable to macrolides or fluoroquinolones in mild-to-moderate CAP and thus represents a viable treatment option. Considering the lack of recent trials, it warrants large-scale clinical trials.
Collapse
Affiliation(s)
- Sang-Ho Choi
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
- Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Antoni Cesar
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| | - Timothy Arthur Chandos Snow
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| | - Naveed Saleem
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| | - Nishkantha Arulkumaran
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| | - Mervyn Singer
- Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, United Kingdom
| |
Collapse
|
4
|
Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class. Antibiotics (Basel) 2020; 9:antibiotics9120905. [PMID: 33327437 PMCID: PMC7764829 DOI: 10.3390/antibiotics9120905] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 12/08/2020] [Accepted: 12/11/2020] [Indexed: 12/03/2022] Open
Abstract
Oral tetracyclines have been used in clinical practice for over 60 years. Overall, one of the most common indications for use of oral tetracyclines is for treatment of adult outpatients with lower respiratory tract infections, including community-acquired pneumonia (CAP). Despite the longstanding use of oral tetracyclines, practice patterns indicate that they are often considered after other guideline-concordant oral CAP treatment options (namely macrolides, fluoroquinolones, and β-lactams). However, there are growing resistance or safety concerns with the available oral agents listed for outpatients with CAP in the updated American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) CAP guidelines, especially among patients with comorbidities or notable risk factors for resistant pathogens. Given the need for alternative oral agents to macrolides, fluoroquinolones, and beta-lactams for adult outpatients with CAP, this review summarizes the literature on the use of oral tetracyclines (i.e., doxycycline, minocycline, and omadacycline) for this indication. As part of this review, we described their mechanism of action, common mechanisms of resistance, susceptibility profiles against common CAP pathogens, pharmacokinetics, pharmacodynamics, clinical data, and safety. The intent of the review is to highlight the important considerations when deciding between doxycycline, minocycline, and omadacycline for an adult outpatient with CAP in situations in which use of an oral tetracycline is warranted.
Collapse
|
5
|
Antibiotic susceptibility of Neochlamydia hartmanellae and Parachlamydia acanthamoebae in amoebae. Microbes Infect 2015; 17:761-5. [PMID: 26279002 DOI: 10.1016/j.micinf.2015.08.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Revised: 08/03/2015] [Accepted: 08/04/2015] [Indexed: 11/24/2022]
Abstract
Parachlamydia acanthamoebae and Neochlamydia hartmanellae are Chlamydia-related bacteria naturally infecting free-living amoebae. These strict intracellular bacteria might represent emerging pathogens. Recent studies report an association with lower respiratory tract infections, especially with pneumonia where they have been identified as a potential causative agent in 1-2% of cases. In this study, we defined the antibiotic susceptibility of N. hartmanellae, two strains of P. acanthamoebae and two yet unclassified Parachlamydiaceae strains using a quantitative approach. We confirmed the results obtained earlier for P. acanthamoebae strain Bn9 in an observational study. Macrolides (MICs < 0.06-0.5 μg/ml), rifampicin (MICs 0.25-2) and doxycycline (2-4 μg/ml) were active against P. acanthamoebae strains and Neochlamydia. All strains were resistant to amoxicillin, ceftriaxone and imipenem (MIC ≥32 μg/ml). Similarly to other Chlamydia-related bacteria, all investigated Parachlamydiaceae were resistant to quinolones (MICs ≥ 16 μg/ml). Therefore, we recommend a treatment with macrolides for Parachlamydia-associated pneumonia.
Collapse
|
6
|
Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 2015; 45:455-60. [PMID: 25801348 DOI: 10.1016/j.ijantimicag.2014.12.031] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Accepted: 12/30/2014] [Indexed: 10/24/2022]
Abstract
Multidrug-resistant (MDR) Acinetobacter baumannii infections have emerged as a serious threat worldwide. As novel agents have yet to be developed, understanding the effectiveness and safety of older antibiotics has become a priority. The purpose of this systematic review was to summarise the available clinical evidence on the use of tetracyclines for the treatment of A. baumannii infections. Ten retrospective studies regarding doxycycline and minocycline for the treatment of 185 A. baumannii infections (of which 65.4% were respiratory infections and 13% were bloodstream infections) in 156 patients were available. In most cases (86.4%), tetracyclines were administered in combination with another agent. The usual dosage of doxycycline or minocycline was 100mg intravenous or per os twice daily (usually with a 200mg loading dose for minocycline). Clinical success was achieved in 120 (76.9%) of 156 patients; in 87 (71.9%) of 121 respiratory infections and in 21 (87.5%) of 24 bloodstream infections. Twenty-two deaths occurred in 100 recorded cases. Microbiological eradication was attained in 72 (71.3%) of 101 available cases and documented microbiological eradication was reached in 59 (66.3%) of 89 available cases. Adverse events were noted in only 1 of 88 cases. Overall, although tetracycline-containing regimens showed encouraging results, more data from larger comparative trials are required to establish a role for these antibiotics in the treatment of MDR A. baumannii infections.
Collapse
Affiliation(s)
- Matthew E Falagas
- Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece; Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
| | - Konstantinos Z Vardakas
- Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece
| | - Anastasios Kapaskelis
- Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece
| | - Nikolaos A Triarides
- Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece
| | | |
Collapse
|
7
|
Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis. Int J Antimicrob Agents 2015; 45:406-12. [PMID: 25717028 DOI: 10.1016/j.ijantimicag.2014.11.017] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 10/31/2014] [Accepted: 11/23/2014] [Indexed: 12/23/2022]
Abstract
The objective of this study was to assess the activity of amikacin in combination with doxycycline against clinical strains of Mycobacterium tuberculosis in the search for new strategies against multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. The study included 28 clinical M. tuberculosis strains, comprising 5 fully susceptible, 1 isoniazid-resistant, 17 MDR, 1 poly-resistant (streptomycin/isoniazid), 1 rifampicin-resistant and 3 XDR isolates, as well as the laboratory strain M. tuberculosis H37Rv. Minimum inhibitory concentrations (MICs) were determined using a modified chequerboard methodology in a BACTEC™ MGIT™ 960 System. Fractional inhibitory concentration indices (FICIs) were calculated, and synergy, indifference or antagonism was assessed. Whole-genome sequencing was performed to investigate the genetic basis of synergy, indifference or antagonism. The MIC50 and MIC90 values (MICs that inhibit 50% and 90% of the isolates, respectively) were, respectively, 0.5 mg/L and 1.0 mg/L for amikacin and 8 mg/L and 16 mg/L for doxycycline. The combination of amikacin and doxycycline showed a synergistic effect in 18 of the 29 strains tested and indifference in 11 strains. Antagonism was not observed. A streptomycin resistance mutation (K43R) was associated with indifference. In conclusion, the benefit of addition of doxycycline to an amikacin-containing regimen should be explored since in vitro results in this study indicate either synergy or indifference. Moreover, doxycycline also has immunomodulatory effects.
Collapse
|
8
|
Bantar C, Schell C, Posse G, Limansky A, Ballerini V, Mobilia L. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2008; 61:309-14. [PMID: 18375084 DOI: 10.1016/j.diagmicrobio.2008.02.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2007] [Revised: 02/08/2008] [Accepted: 02/24/2008] [Indexed: 02/06/2023]
Abstract
To assess potential alternative options for the treatment of infections caused by Acinetobacter baumannii, we performed time-kill studies of doxycycline and tigecycline using several isolates recovered from patients residing in 10 different cities in Argentina. Imipenem and sulbactam were also included for comparison purposes. Eleven isolates representing 5 distinctive clones, or isolates with different susceptibility patterns within the same clone, were selected. Tubes containing cation-supplemented Mueller-Hinton broth with and without antibiotics were seeded with a log-phase inoculum of roughly 5 x 10(5) CFU/mL. By using the viable counts determined at 2-, 4-, 6-, 8-, and 24-h intervals after inoculation, a 24-h time-kill curve was constructed for each isolate. No bactericidal activity (defined as a >or=3-log(10) CFU/mL decrease in the viable cell counts with respect to the original inoculum) was observed at any time with sulbactam (4 microg/mL) or tigecycline (1 microg/mL), whereas low bactericidal rate (18% of the isolates) was shown for doxycycline (1 microg/mL) and sulbactam (16 microg/mL) after 24 h of incubation. Doxycycline (4 microg/mL) and tigecycline (8 microg/mL) displayed bactericidal activity at 24 h of incubation against 36% and 54% of the isolates, respectively, including the carbapenem-resistant isolate. Corresponding values for imipenem (1 and 4 microg/mL) against the 10 carbapenem-susceptible isolates were 60% and 90%, respectively. The present study confirms the in vitro efficacy of imipenem against A. baumannii, suggests that doxycycline could be a suitable, cost-effective, alternative option in some instances, and sheds light on the potential role of tigecycline in the treatment of infections with this organism.
Collapse
Affiliation(s)
- Carlos Bantar
- Laboratorio Domingo I. Nanni, Paraná, Entre Ríos, Argentina.
| | | | | | | | | | | |
Collapse
|
9
|
Fragoulis KN, Handrinou E, Papadopoulos V, Dardoufas K, Falagas ME. Delayed effusive pericarditis and recurrent pleural effusion after radiation treatment for Hodgkin's disease responsive to per os doxycycline. Eur J Haematol 2006; 76:176-9. [PMID: 16405442 DOI: 10.1111/j.0902-4441.2005.00577.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
We present our experience with a patient with effusive pericarditis and recurrent pleural effusion that first developed 23 yr after radiation treatment for the nodular sclerosis type of Hodgkin's disease. Extensive diagnostic work up including pericardial and pleural biopsy, excluded any other cause (than radiation) of the recurrent pleural effusion. Pericarditis and pleural effusion were not controlled with regimens including steroid and non-steroid anti-inflammatory agents. The fluid collections improved only with per os doxycycline (100 mg twice a day). Four episodes of recurrent pleural effusions were also controlled with per os doxycycline. Although the concentration of doxycycline in the pericardial and pleural fluid when given orally is smaller compared with that achieved by direct installation of the agent, the fact that all episodes of pleural effusion improved with an agent commonly used for pleurodesis is intriguing.
Collapse
|
10
|
Boselli E, Allaouchiche B. [Pulmonary diffusion of antibiotics. Critical analysis of the literature]. ANNALES FRANCAISES D'ANESTHESIE ET DE REANIMATION 2001; 20:612-30. [PMID: 11530749 DOI: 10.1016/s0750-7658(01)00439-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVES Collect exhaustive data from the literature concerning the diffusion of antibiotics into lung tissue and calculate their inhibitory quotient towards the germs most frequently encountered in pulmonary infections. DATA SOURCES Review of the literature. Data collected from the Medline database with the key words: lung, diffusion, disposition, antibiotics. Inhibitory quotients calculated from these data. RESULTS The results were relatively similar for the different types of samples, though some differences existed between the studies. These differences were caused in particular by methodological difficulties for the tissue dosage of antibiotics. CONCLUSION Further standardized studies, measuring in particular the antibiotic concentration in the epithelial lining fluid and in the alveolar macrophages, are necessary to obtain more reliable results in terms of inhibitory quotients. Only clinical studies, perhaps with the help of these data, could establish the real efficiency of antibiotics in lung infections.
Collapse
Affiliation(s)
- E Boselli
- Service d'anesthésie-réanimation, Hôtel-Dieu, 1, place de l'Hôpital, 69288 Lyon, France
| | | |
Collapse
|
11
|
Cruciani M, Gatti G, Cazzadori A, Concia E. Pharmacokinetics of antimicrobial agents in the respiratory tract. ZENTRALBLATT FUR BAKTERIOLOGIE : INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY 1996; 284:1-31. [PMID: 8837365 DOI: 10.1016/s0934-8840(96)80150-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The ability of antibiotics to penetrate into the respiratory tract has been investigated at several sites, namely, sputum and bronchial secretions, tissue homogenates, pleural fluid and, more recently, epithelial lining fluid and alveolar macrophages. The major reason for such investigations is that these data may be helpful to a more thorough understanding of drug distribution in the lung tissue and fluids and to a more accurate prediction of clinical outcome. However, the study of drug concentration at each of these sites presents problems in terms of methodology and data interpretation. The advantages and disadvantages of each of these methods are considered, and the data on penetration of betalactams, aminoglycosides, macrolides, fluoroquinolones and other antimicrobial agents (including antifungal and antiprotozoan drugs) are reviewed.
Collapse
Affiliation(s)
- M Cruciani
- Institute of Immunology and Infectious Diseases, Università degli Studi di Verona, Ospedale Civile Maggiore, Italy
| | | | | | | |
Collapse
|
12
|
Abstract
Optimal antibiotic regimens and duration of treatment are not universally agreed on for community-acquired or nosocomial pneumonias. Experience suggests that community-acquired pneumonias may be treated for less than 2 weeks with a combination of intravenous and oral antibiotics of appropriate spectrum that penetrate the lung, have a good safety profile, do not foster the development of resistance, and are cost-effective. After initial intravenous therapy, oral switch therapy may be begun as soon as the patient defervesces clinically, which is usually 3 days after admission. Switching to oral therapy does not invariably lead to earlier hospital discharge. There is no "standard of care" for pneumonias, but guidelines for empiric use have existed for decades. The least expensive beta-lactamase stable antibiotic should be used as monotherapy for the empiric treatment of community-acquired pneumonia. Because community-acquired atypical pneumonias are clinically distinct from bacterial pneumonias owing to their extrapulmonary features, clinicians should be able to differentiate atypical pneumonias from bacterial pneumonias, which permits prompt and appropriate treatment. Nosocomial pneumonias remain a difficult diagnostic challenge. Therapeutically the most important principle in treating nosocomial pneumonia is to provide for double-drug coverage against P. aeruginosa. Differentiation of respiratory tract colonization from respiratory tract invasion remains the central key issue in patients with pulmonary infiltrates acquired during hospitalization. Most patients complete their course of intravenous therapy for nosocomial pneumonia leaving little or no time for completion of their therapy by oral antibiotics. Hospital-acquired atypical pneumonias are largely limited to legionnaires' disease, which is a more difficult diagnosis than in the community-acquired setting. Clinicians taking care of patients with pneumonia should employ a simplified therapeutic approach using a single drug for community-acquired infections. The use of additional antibiotics to increase gram-negative coverage is medically unjustified and not cost-effective and is to be discouraged. The most cost-effective strategy for the treatment of community-acquired pneumonias is to switch the patient from an intravenous to an oral antibiotic as soon as the patient clinically defervesces and is able to take oral medications. Antimediator therapies have no role in the treatment of community-acquired or nosocomial pneumonias.
Collapse
Affiliation(s)
- B A Cunha
- Infectious Disease Division, Winthrop-University Hospital, Mineola, New York, USA
| |
Collapse
|